Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an
increasing incidence. The treatment of VTE is undergoing tremendous changes with the …

Aim Apixaban is an orally active inhibitor of coagulation factor Xa and is eliminated by
multiple pathways, including renal and non‐renal elimination. Non‐renal elimination …

A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

The efficacy, safety, and convenience of direct oral anticoagulants (DOACs) have led to
these agents being established as therapeutic alternatives to vitamin K antagonists (VKAs) …

Background Activated charcoal is commonly used to manage overdose or accidental
ingestion of medicines. This study evaluated the effect of activated charcoal on apixaban …

The well accepted “free drug hypothesis” for small-molecule drugs assumes that only the
free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect …

Today, direct oral anticoagulants (DOAC) are widely used alternatives to Vitamin-K
antagonists (VKA). Women of reproductive age may become pregnant during …

Objective Apixaban is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein.
The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the …

A two-step degradation–reconstruction approach to the carbon-14 radiolabeling of alkyl
carboxylic acids is presented. Simple activation via redox-active ester formation was …